346 related articles for article (PubMed ID: 16499576)
1. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
Bakke H; Samdal HH; Holst J; Oftung F; Haugen IL; Kristoffersen AC; Haugan A; Janakova L; Korsvold GE; Krogh G; Andersen EA; Djupesland P; Holand T; Rappuoli R; Haneberg B
Scand J Immunol; 2006 Mar; 63(3):223-31. PubMed ID: 16499576
[TBL] [Abstract][Full Text] [Related]
2. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
Treanor J; Nolan C; O'Brien D; Burt D; Lowell G; Linden J; Fries L
Vaccine; 2006 Jan; 24(3):254-62. PubMed ID: 16129526
[TBL] [Abstract][Full Text] [Related]
3. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
5. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
[TBL] [Abstract][Full Text] [Related]
6. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
7. Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant.
Haneberg B; Dalseg R; Oftung F; Wedege E; Høiby EA; Haugen IL; Holst J; Andersen SR; Aase A; Meyer Naess L; Michaelsen TE; Namork E; Haaheim LR
Dev Biol Stand; 1998; 92():127-33. PubMed ID: 9554266
[TBL] [Abstract][Full Text] [Related]
8. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
Muhamed G; Greenbaum E; Zakay-Rones Z
Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness.
Bizanov G; Janakova L; Knapstad SE; Karlstad T; Bakke H; Haugen IL; Haugan A; Samdal HH; Haneberg B
Scand J Immunol; 2005 Jun; 61(6):503-10. PubMed ID: 15963044
[TBL] [Abstract][Full Text] [Related]
10. Long- and short-time immunological memory in different strains of mice given nasally an adjuvant-combined nasal influenza vaccine.
Asanuma H; Fujihashi K; Miyakoshi T; Yoshikawa T; Fujita-Yamaguchi Y; Kojima N; Nakata M; Suzuki Y; Tamura S; Kurata T; Sata T
Vaccine; 2007 Sep; 25(39-40):6975-80. PubMed ID: 17716790
[TBL] [Abstract][Full Text] [Related]
11. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
[TBL] [Abstract][Full Text] [Related]
12. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
[TBL] [Abstract][Full Text] [Related]
13. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.
Huang J; Garmise RJ; Crowder TM; Mar K; Hwang CR; Hickey AJ; Mikszta JA; Sullivan VJ
Vaccine; 2004 Dec; 23(6):794-801. PubMed ID: 15542204
[TBL] [Abstract][Full Text] [Related]
14. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
Tamura SI; Kurata T
Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
[TBL] [Abstract][Full Text] [Related]
15. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants.
Samdal HH; Bakke H; Oftung F; Holst J; Haugen IL; Korsvold GE; Kristoffersen AC; Krogh G; Nord K; Rappuoli R; Berstad AK; Haneberg B
Hum Vaccin; 2005; 1(2):85-90. PubMed ID: 17038826
[TBL] [Abstract][Full Text] [Related]
16. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
17. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
18. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
[TBL] [Abstract][Full Text] [Related]
19. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza.
Vajdy M; Baudner B; Del Giudice G; O'Hagan D
Clin Immunol; 2007 May; 123(2):166-75. PubMed ID: 17349825
[TBL] [Abstract][Full Text] [Related]
20. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes.
Moldoveanu Z; Clements ML; Prince SJ; Murphy BR; Mestecky J
Vaccine; 1995 Aug; 13(11):1006-12. PubMed ID: 8525683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
